// App-Quantinova.ai

FRI-127 : Hypogonadal Patients with Crohn's disease Benefit from Treatment with Testosterone Further Data from an Ongoing, Long-Term, Observational Registry Study

Researchers

Presenter

  • Farid Saad

Principal Investigators

  • Mahmoud Nasser

  • Ahmad Haider

  • Aksam A Yassin

  • Winfried Kurtz

  • Gheorghe Doros

  • Monika Fijak

  • Linda Vignozzi

  • Louis J Gooren

Medical Centers

  • Boston University School of Public Health, Boston, MA

  • University of Aleppo, Aleppo, Syria

  • University of Florence, Florence, Italy

  • Private Urology Practice, Bremerhaven, Germany

  • Segeberger Kliniken, Norderstedt, Germany

  • VU University Medical Center, Amsterdam, Netherlands

  • Klinikum Bremerhaven-Reinkenheide, Bremerhaven, Germany

  • Justus-Liebig University of Giessen, Giessen, Germany

Locations

  • Italy

  • Netherlands

  • Germany

  • United States

  • Syria

Companies

  • Bayer

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Crohn's disease

  • Osteoporosis

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

  • High sensitivity C-reactive protein

  • Testosterone

  • Twist-related protein 2

Drug/Treatment

  • LPCN 1111

  • Hydroxyzine

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved